We offer a singularly strong pipeline, with:
Our clinical data is revealing new immunosuppressive metabolic pathway activation, and we have a new combination Tx approach under development.
We have clinical trials in progress that are targeting:
In all trials, we have seen one or more of the following clinical signals:
We have a deep clinical biomarker database: